We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





MeMed Displays Disruptive Technology Award Finalist COVID-19 Severity Test at AACC 2021

By LabMedica International staff writers
Posted on 29 Sep 2021
Print article
Image: The MeMed Key platform (Photo courtesy of MeMed)
Image: The MeMed Key platform (Photo courtesy of MeMed)

MeMed (Haifa, Israel) displayed the MeMed COVID-19 Severity Test, the Disruptive Technology Award finalist, at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo, the largest global scientific conference & tradeshow in the field of laboratory medicine.

MeMed was named a finalist for the American Association of Clinical Chemistry’s (AACC) Disruptive Technology Award for the MeMed COVID-19 Severity test, which stratifies the risk that a patient with COVID-19 will experience severe outcomes. It reads the immune-system in real time to accurately determine whether SARS-CoV-2 patients are likely to have a severe outcome.

MeMed COVID-19 Severity is a pioneering host response technology that measures multiple proteins from a serum sample and applies machine learning to stratify the risk that a patient with COVID-19 will experience severe outcomes. The test runs in 15 minutes on the company’s cutting edge multi-purpose platform, MeMed Key, for quantitative diagnostic immunoassays that opens the way to central lab performance at the point-of-need, using chemiluminescence detection technology. MeMed Key provides accuracy similar to large central lab immunoassay platforms in a miniaturized and point-of-need format. It has a wide dynamic range from single pg/ml to µg/ml, which opens the way to measuring host and pathogen based immunoassays that are currently only measurable at the central lab.

Also on display at the event was MeMed BV, a host-immune response assay that can aid to distinguish between bacterial and viral infections delivering results in 15 minutes from serum. MeMed BV computationally integrates the levels of three host immune proteins into a simple score indicating the likelihood of a bacterial immune response/co-infection versus a viral immune response. Run on the compact MeMed Key, it is the only test for distinguishing bacterial from viral infections that has been validated in multinational, double-blind and external clinical studies.

Related Links:
MeMed 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Turbidimetric Control
D-Dimer Turbidimetric Control

Print article
AACC

Channels

Clinical Chemistry

view channel
Image: Wireless Point-of-Care Testing for Hepatitis B Virus (Photo courtesy of Chulalongkorn University)

Wireless Hepatitis B Test Kit Completes Screening and Data Collection in One Step

Hepatitis B, a significant global health concern, is responsible for chronic liver diseases like cirrhosis and liver cancer which is one of the most common cancers worldwide. The challenge with hepatitis... Read more

Molecular Diagnostics

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Novel Immunoassays Enable Early Diagnosis of Antiphospholipid Syndrome

Antiphospholipid syndrome (APS) is an autoimmune disorder that typically presents as venous or arterial thrombosis and/or pregnancy loss. Diagnosing APS can be difficult as its symptoms often resemble... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Pathology

view channel
Image: The photoacoustic spectral response sensing instrument is based on low-cost laser diodes (Photo courtesy of Khan et al., doi 10.1117/1.JBO.29.1.017002)

Compact Photoacoustic Sensing Instrument Enhances Biomedical Tissue Diagnosis

The pursuit of precise and efficient diagnostic methods is a top priority in the constantly evolving field of biomedical sciences. A promising development in this area is the photoacoustic (PA) technique.... Read more

Industry

view channel
Image: The companies will develop genetic testing systems based on capillary electrophoresis sequencers (Photo courtesy of 123RF)

Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems

Sysmex Corporation (Kobe, Japan) and Hitachi High-Tech Corporation (Tokyo, Japan) have entered into a collaboration for the development of genetic testing systems using capillary electrophoresis sequencers... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.